N. Nora Bennani, MD, on Diving Deeper Into T-Cell Lymphomas
The assistant professor at Mayo Clinic School of Medicine shared her outlook and predictions on research with T-cell lymphomas.
“T-cell lymphomas, we know, are a heterogeneous group of diseases. But the more we do in terms of genomics, the more we are able to categorize this disease even further into subcategories that have similar responses or non-responses to various therapies. So, if we understand better the various subgroups of T-cell lymphoma, we will know better how to treat them.”
Mayo Clinic is conducting a phase 1 clinical study (NCT03017820) of VSV-IFNβ-NIS, an engineered Vesicular Stomatitis Virus (VSV) therapy, for patients with relapsed/refractory multiple myeloma and T-cell lymphoma (TCL). The trial is currently recruiting. VSV-IFNβ-NIS is a bullet-shaped rhabdovirus which encodes both interferon beta (IFNβ) and sodium iodine symporter (NIS) with particular tumor cell tropism. Viral IFNβ boosts the host's anti-tumor immune response and serves as an indicator of viral proliferation.
The trial’s design was presented at the
REFERENCE
Bennani NN, Cook J, Geyer SM, et al. Phase I trial of systemic administration of vesicular stomatitis virus genetically engineered to express NIS and human interferon, in patients with relapsed or refractory multiple myeloma, lymphomas, or histiocytic/dendritic cell neoplasms. Presented at: ASH 2023 Annual Meeting; December 9-12; San Diego, California. Abstract 5004
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025